ANUHPHR

Anuh Pharma Share Price

₹217.05 +0.4 (0.18%)

26 Dec, 2024 04:43

SIP TrendupStart SIP in ANUHPHR

Start SIP

Performance

  • Low
  • ₹212
  • High
  • ₹224
  • 52 Week Low
  • ₹208
  • 52 Week High
  • ₹246
  • Open Price₹216
  • Previous Close₹216
  • Volume21,657

Investment Returns

  • Over 1 Month + 11.36%
  • Over 3 Month + 6.4%
  • Over 6 Month -2.49%
  • Over 1 Year + 45.28%
SIP Lightning

Smart Investing Starts Here Start SIP with Anuh Pharma for Steady Growth!

Invest Now

Anuh Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 18.4
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 1,088
  • P/B Ratio
  • 3.7
  • Average True Range
  • 8.97
  • EPS
  • 11.78
  • Dividend Yield
  • 1.2
  • MACD Signal
  • 5.58
  • RSI
  • 53.66
  • MFI
  • 70.35

Anuh Pharma Financials

Anuh Pharma Technicals

EMA & SMA

Current Price
₹217.05
+ 0.4 (0.18%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹216.22
  • 50 Day
  • ₹210.19
  • 100 Day
  • ₹209.92
  • 200 Day
  • ₹205.10

Resistance and Support

217.38 Pivot Speed
  • R3 236.27
  • R2 230.08
  • R1 223.57
  • S1 210.87
  • S2 204.68
  • S3 198.17

What's your outlook on Anuh Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Anuh Pharma has an operating revenue of Rs. 639.85 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 12% is healthy, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 68 which is a FAIR score but needs to improve its earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Anuh Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-08 Quarterly Results
2024-08-09 Quarterly Results
2024-05-17 Audited Results & Final Dividend
2024-02-09 Quarterly Results
2023-11-10 Quarterly Results

Anuh Pharma F&O

Anuh Pharma Shareholding Pattern

69.92%
0.02%
0%
26.27%
3.79%

About Anuh Pharma

  • NSE Symbol
  • ANUHPHR
  • BSE Symbol
  • 506260
  • Joint Managing Director
  • Mr. Ritesh B Shah
  • ISIN
  • INE489G01022

Similar Stocks to Anuh Pharma

Anuh Pharma FAQs

Anuh Pharma share price is ₹217 As on 26 December, 2024 | 04:29

The Market Cap of Anuh Pharma is ₹1087.7 Cr As on 26 December, 2024 | 04:29

The P/E ratio of Anuh Pharma is 18.4 As on 26 December, 2024 | 04:29

The PB ratio of Anuh Pharma is 3.7 As on 26 December, 2024 | 04:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23